Last Price
0.345
Today's Change
+0.02 (6.15%)
Day's Change
0.325 - 0.345
Trading Volume
7,955,636
Market Cap
605 Million
Shares Outstanding
1 Billion
Avg Volume
6,229,417
Avg Price (50 Days)
0.29
Avg Price (200 Days)
0.20
PE Ratio
-34.50
EPS
-0.01
Earnings Announcement
28-Jul-2024
Previous Close
0.33
Open
0.33
Day's Range
0.325 - 0.345
Year Range
0.115 - 0.4
Trading Volume
7,955,636
1 Day Change
6.15%
5 Day Change
-2.82%
1 Month Change
18.97%
3 Month Change
43.75%
6 Month Change
72.50%
Ytd Change
81.58%
1 Year Change
155.56%
3 Year Change
292.05%
5 Year Change
64.29%
10 Year Change
444.74%
Max Change
-99.71%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.